Compare 10X Genomics Inc (TXG) vs Zillow Group Inc Class A (ZG) Price & Performance

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.

Zillow Group (ZG) trades at $33.03, down 6.48% over 24 hours, reflecting bearish technical signals amid a challenging housing market. The stock shows mixed fundamentals with a high P/E ratio of 143.57 but improving revenue growth to $2.58B in 2025 and a return to net profitability. Recent news highlights Zillow's shift to an integrated transaction platform and a settled FTC lawsuit, while analyst consensus remains cautiously optimistic with a $47.56 price target.

The outlook balances growth potential from Zillow's monetization strategy against near-term headwinds like elevated interest rates dampening home sales. Risks include execution challenges in the business model transition and competitive pressures, but institutional buying and earnings beats suggest underlying strength. Investors should weigh the high valuation against improving cash flow and market positioning.